| Biochip: A Promise for Individualized Cancer Treatment |
| 2008/06/18 |
|
China's biochip industry has rolled out some 400 types of biochips A meeting, jointly sponsored by the Ministry of Science and Technology and the General Administration of Quality Supervision, Inspection and Quarantine, was recently held to discuss applications of biochips in medicine and food safety. Participants believed that biochips are of a promising perspective in treating cancers on an individualized basis. For example, Prof. ZHAN Qimin, Vice-President of the Chinese Academy of Medical Sciences, has obtained 285 genes displaying different expressions in the study of breast cancers, using the 22K Human Genome Array developed by CapitalBio. A further molecular interpretation of 285 genes has led to preliminary expression spectrums at the molecular level. These spectrums are the theoretical evidences for providing individualized treatment for breast cancer patients. Meanwhile, Prof. HE Jie, Vice-President of Tumor Hospital under Chinese Academy of Medical Sciences, and coworkers have discovered miRNA molecules that cause lymph node metastasis using biochips, making molecular markers available for studying esophageal cancer, and allowing an improved clinical classification for individualized treatment. Participants agreed that individualized treatment can effectively improve cancer treatment, and address insufficient or excessive treatment, bringing more benefits and hope to patients. Intelligent and Multifunctional Heparanase A study team, headed by Prof. XING Xinhui, Director of Tsinghua University Institute of Biochemistry, has for the first time developed a concept of intelligent and multifunctional enzyme, in an attempt to produce an enzyme with process integration and control functions, using chemical/molecular/biological means. Researchers also developed the technologies to produce intelligent and multifunctional heparanase. A six-month limited trial production has shown that the intelligent and multifunctional heparanase can be used to prepare low-molecule heparin, through a simple, clean, safe, and effective process. Researchers recombined intelligent and multifunctional heparanase strains using the cloned heparanase-I gene. They also brought down both the production and application costs, through fast tracing, control, purification, and fixation of the activity of intelligent enzyme. The intelligent and multifunctional heparanase-I is able to effectively decompose large-molecule heparin, and make them into the one with low molecules. Using an advanced bioreactor with a super filter, researchers have rolled out low-molecule heparin products with a molecule weight ranging between 5000-6000. In addition, the advanced bioreactor can be used to prepare a super low-molecule heparin with a molecule weight ranging between 2000-3000. |